Skip to main content

Articles

Page 1 of 112

  1. Approximately 20% of breast cancers overexpress ErbB2/HER2/Neu, a receptor tyrosine kinase. Our previous studies demonstrated that HER2 interacts with the calcium pump, PMCA2, and the scaffolding molecules, NH...

    Authors: Jaekwang Jeong, Kwangmin Yoo, Jongwon Lee, Jae Hun Shin, Jungmin Choi and John Wysolmerski
    Citation: Breast Cancer Research 2025 27:85
    Content type: Research Published on:

  3. Mammographic density is known to decrease over time in postmenopausal women. Longitudinal changes in mammographic density prior to breast cancer diagnosis have been widely discussed and less density reduction ...

    Authors: Nataliia Moshina, Jonas Gjesvik, Tone Hovda, Henrik W. Koch, Heinrich A. Backmann and Solveig Hofvind
    Citation: Breast Cancer Research 2025 27:83
    Content type: Research Published on:

  4. Depression could affect breast cancer risk; however, epidemiologic findings are mixed. We assessed the association of breast cancer risk with self-reported history of diagnosed depression and time-dependent an...

    Authors: Mary V. Díaz-Santana, Jihye Park, Molly Rogers, Katie M. O’Brien, Hazel B. Nichols, Aimee A. D’Aloisio, Deborah B. Bookwalter, Dale P. Sandler and Clarice R. Weinberg
    Citation: Breast Cancer Research 2025 27:82
    Content type: Research Published on:

  5. Aging is the greatest risk factor for breast cancer, and although epithelial cells are the source of carcinomas, epithelial changes alone do not fully explain cancer susceptibility. Fibroblasts and macrophages...

    Authors: Eric G. Carlson, Jennifer C. Lopez, Yukiko Yamaguchi, Jackson Gibson, Saul J. Priceman and Mark A. LaBarge
    Citation: Breast Cancer Research 2025 27:81
    Content type: Research Published on:

  6. This study aimed to develop a BI-RADS network (DL-UM) via integrating ultrasound (US) and mammography (MG) images and explore its performance in improving breast lesion diagnosis and management when collaborat...

    Authors: Ziting Xu, Shengzhou Zhong, Yang Gao, Jiekun Huo, Weimin Xu, Weijun Huang, Xiaomei Huang, Chifa Zhang, Jianqiao Zhou, Qing Dan, Lian Li, Zhouyue Jiang, Ting Lang, Shuying Xu, Jiayin Lu, Ge Wen…
    Citation: Breast Cancer Research 2025 27:80
    Content type: Research Published on:

  7. Mutations in ESR1 play a critical role in resistance to endocrine therapy (ET) in hormone receptor-positive (HR +)/HER2- metastatic breast cancer (MBC). Testing for ESR1 mutations is essential for guiding treatme...

    Authors: Konstantinos Venetis, Giulia Cursano, Roberta Scafetta, Pier Paolo Maria Berton Giachetti, Alberto Concardi, Elisa De Camilli, Marianna D’Ercole, Eltjona Mane, Chiara Frascarelli, Antonio Marra, Sara Gandini, Francesco Pepe, Simone Scagnoli, Silvia Maria Rossi, Raffaella Troiano, Elena Speziale…
    Citation: Breast Cancer Research 2025 27:79
    Content type: Research Published on:

  9. Transcriptomic features of breast cancer locoregional recurrence (LRR) remain poorly understood. We therefore sought to investigate transcriptomic features associated with LRR in newly diagnosed invasive breas...

    Authors: Timothy J. Robinson, Casey L. Liveringhouse, Christopher Wilson, Sam Friedman, Justyn Nakashima, Matthew N. Mills, Jacob D. Purcell, Nicholas B. Figura, Du Dongliang, Ram Thapa, Eric Welsh, Kamran A. Ahmed, G. Daniel Grass, Brooke L. Fridley and Roberto Diaz
    Citation: Breast Cancer Research 2025 27:77
    Content type: Research Published on:

  10. Cancer-related fatigue (CRF) is a common symptom in breast cancer patients and survivors, which can substantially impair quality of life. Previous studies suggested that CRF may be associated with poorer survi...

    Authors: Philipp Heumann, Axel Benner, Sabine Behrens, Jenny Chang-Claude and Petra Seibold
    Citation: Breast Cancer Research 2025 27:76
    Content type: Research Published on:

  12. In tumors rich in adipose tissue, angiogenesis is a critical factor in promoting cancer cell metastasis. However, the connection between angiogenesis and the mechanisms driving adipose metabolic remodeling in ...

    Authors: Xiao Ma, Baojian Zhang, Xuezhe Yin, ShiPeng Yang, Zhenhua Lin, Yang Yang and Xianchun Zhou
    Citation: Breast Cancer Research 2025 27:74
    Content type: Research Published on:

  13. The RANK pathway has been extensively investigated for its role in bone resorption; however, its significance extends beyond bone metabolism. Preclinical models suggest that inhibition of RANK signaling can pr...

    Authors: Andrea Vethencourt, Eva M. Trinidad, Eduard Dorca, Anna Petit, M. Teresa Soler-Monsó, Marina Ciscar, Alexandra Barranco, Gema Pérez-Chacón, María Jimenez, Mario Rodríguez, Clara Gomez-Aleza, Elvira Purqueras, Enrique Hernández-Jiménez, Ander Urruticoechea, Idoia Morilla, Isaac Subirana…
    Citation: Breast Cancer Research 2025 27:68
    Content type: Research Published on:

  14. Circulating immune cells play a crucial role in the anti-tumour immune response, yet the systemic immune system in metastatic breast cancers is not fully characterised. Investigating the cellular and molecular...

    Authors: S. Mangiola, R. Brown, C. Zhan, J. Berthelet, S. Guleria, C. Liyanage, S. Ostrouska, J. Wilcox, M. Merdas, P. Fuge-Larsen, C. Bell, J. Schröder, L. A. Mielke, J. M. Mariadason, S. Chang-Hao Tsao, Y. Chen…
    Citation: Breast Cancer Research 2025 27:73
    Content type: Research Published on:

  15. Little is known regarding biomechanical properties derived from multifrequency MR elastography temporal changes during neoadjuvant chemotherapy (NAC) and associated with pathologic complete response (pCR) and ...

    Authors: Xiaoxia Wang, Yao Huang, Jinfang Shi, Ying Cao, Huifang Chen, Lan Li, Lu Wang, Sun Tang, Xueqin Gong, Haiping Huang, Ting Yin and Jiuquan Zhang
    Citation: Breast Cancer Research 2025 27:72
    Content type: Research Published on:

  16. 8MW0511 is a novel, long-acting recombinant human granulocyte-colony stimulating factor (G-CSF) produced by the fusion of the N-terminus of highly active modified G-CSF with the C-terminus of human serum album...

    Authors: Biyun Wang, Xiuchun Chen, Hongtao Li, Jing Sun, Xinjian Jia, Tao Sun, Yumin Yao, Jingfen Wang, Jincheng Li, Xujuan Wang, Xiaojia Wang, Cuizhi Geng, Yu Ren, Liuzhong Yang, Jun Jia, Yiding Chen…
    Citation: Breast Cancer Research 2025 27:71
    Content type: Research Published on:

  17. Tumor-associated macrophages (TAMs) are key promoters of inflammatory breast cancer (IBC), the most aggressive form of breast cancer. The receptor tyrosine kinase AXL is highly expressed in various cancer type...

    Authors: Lan T. H. Phi, Yating Cheng, Yohei Funakoshi, Francois Bertucci, Pascal Finetti, Steven J. Van Laere, Fang Zou, James P. Long, Suguru Ogata, Savitri Krishnamurthy, James M. Reuben, Jason M. Foulks, Steven L. Warner, Jennifer M. Rosenbluth, Anil K. Sood, Debu Tripathy…
    Citation: Breast Cancer Research 2025 27:70
    Content type: Research Published on:

  18. The tumor microenvironment (TME), particularly the extracellular matrix (ECM), plays a crucial role in regulating breast cancer progression. Among ECM components, collagen type I—accounting for over 90% of fib...

    Authors: Samane Heydari, Fatemeh Tajik, Sadegh Safaei, Fereshteh Kamani, Babak Karami, Shima Dorafshan, Zahra Madjd and Roya Ghods
    Citation: Breast Cancer Research 2025 27:69
    Content type: Review Published on:

  19. Incidence of premenopausal breast cancer (BC) has risen in recent years, though most existing BC prediction models are not generalizable to young women due to underrepresentation of this age group in model dev...

    Authors: Kristen D. Brantley, Michael E. Jones, Rulla M. Tamimi, Bernard A. Rosner, Peter Kraft, Hazel B. Nichols, Katie M. O’Brien, Hans-Olov Adami, Amaia Aizpurua, Amy Berrington de Gonzalez, William J. Blot, Tonje Braaten, Yu Chen, Jessica Clague DeHart, Laure Dossus, Sjoerd Elias…
    Citation: Breast Cancer Research 2025 27:67
    Content type: Research Published on:

  20. Intratumoral heterogeneity of breast cancer cells causes undesired drug resistance and predispose to disease recurrence. We investigate the molecular heterogeneity of breast cancer cells derived from malignant...

    Authors: Soon-Chan Kim, Ga-Hye Kim, Jae-Hyeon Park, Kyung-Hun Lee, Jiwon Koh, Tae-Yong Kim, Dae-Won Lee, Yu-Jin Kim, Seongyeong Kim, Song-Yi Park, Ahrum Min, Young-Kyoung Shin, Seock-Ah Im and Ja-Lok Ku
    Citation: Breast Cancer Research 2025 27:66
    Content type: Research Published on:

  21. Early-stage breast cancer (BC) diagnosis significantly reduces mortality, yet relapse remains a concern due to undetectable minimal residual disease (MRD). Liquid biopsies offer real-time insights into tumor d...

    Authors: Iñaki Comino-Méndez, Jesús Velasco-Suelto, Javier Pascual, Esperanza López-López, Maria Elena Quirós-Ortega, Celia Gaona-Romero, Alejandro Martín-Muñoz, Patricia Losana, Yanira Heredia, Emilio Alba and Angel Guerrero-Zotano
    Citation: Breast Cancer Research 2025 27:65
    Content type: Research Published on:

  22. Neoadjuvant chemotherapy (NAC) is a standard treatment for breast cancer (BC) to shrink tumors and facilitate surgery. However, the molecular underpinnings of response to NAC and prognosis have not been well c...

    Authors: Menghao Dong, Jian Chen, Nannan Lu, Song Wang, Wenhui Wei, Ziming Wang, Jinnan Wang, Jinguo Zhang, Xinghua Han, Fufeng Wang, Qiuxiang Ou, Hua Bao, Xiaopeng Ma, Benjie Shan and Yueyin Pan
    Citation: Breast Cancer Research 2025 27:64
    Content type: Research Published on:

  23. Microtubule associated series/threonine kinase-3 (MAST3) is a member of microtubule associated serine/threonine kinase family (MAST1-4, MAST-like), and the expression and underlying molecular mechanism of MAST...

    Authors: Ning Deng, Wei Kang, Jiang Du, Xuezhu Rong and Qiang Han
    Citation: Breast Cancer Research 2025 27:63
    Content type: Research Published on:

  24. Streamlining the clinical procedure of human epidermal growth factor receptor 2 (HER2) examination is challenging. Previous studies neglected the intra-class variability within both HER2-positive and -negative...

    Authors: Xiaoping Li, Zhiquan Lin, Chaoran Qiu, Yiwen Zhang, Chuqian Lei, Shaofei Shen, Weibin Zhang, Chan Lai, Weiwen Li, Hui Huang and Tian Qiu
    Citation: Breast Cancer Research 2025 27:62
    Content type: Research Published on:

  25. The mechanisms underpinning neoadjuvant chemotherapy-induced vascular endothelial injury in breast cancer remain elusive. Our study aims to demonstrate that Neutrophil Extracellular Traps (NETs) play a pivotal...

    Authors: Linghui Kong, Song Hu, Ying Zhao, Yan Huang, Xiaobing Xiang, Yang Yu, Xiaochun Mao, Kangjie Xie, Xiaoyan Zhu and Pingbo Xu
    Citation: Breast Cancer Research 2025 27:61
    Content type: Research Published on:

  26. Normal breast tissues adjacent to cancer often harbor many of the same genomic alterations as the cancer itself. However, it remains unclear whether histologically normal breast tissues carry genomic changes r...

    Authors: Jiawei Dai, Mariya Rozenblit, Xiaoyue Li, Naing Lin Shan, Yueyue Wang, Shrikant Mane, Michal Marczyk and Lajos Pusztai
    Citation: Breast Cancer Research 2025 27:60
    Content type: Research Published on:

  27. Age and molecular subtypes are important prognostic factors in breast cancer (BC). Here, we explore how age and molecular subtypes influence BC survival in Scotland.

    Authors: Ines Mesa-Eguiagaray, Sarah H. Wild, Linda J. Williams, Kai Jin, Sheila M. Bird, David H. Brewster, Peter S. Hall and Jonine D. Figueroa
    Citation: Breast Cancer Research 2025 27:59
    Content type: Research Published on:

  28. The Nottingham histologic grade is crucial for assessing severity and predicting prognosis in breast cancer, a prevalent cancer worldwide. Traditional grading systems rely on subjective expert judgment and req...

    Authors: Jun Seo Kim, Jeong Hoon Lee, Yousung Yeon, Doyeon An, Seok Jun Kim, Myung-Giun Noh and Suehyun Lee
    Citation: Breast Cancer Research 2025 27:58
    Content type: Research Published on:

  29. Treatment with HER2-targeted therapies is recommended for HER2-positive breast cancer patients with HER2 gene amplification or protein overexpression. Interestingly, recent clinical trials of novel HER2-targeted ...

    Authors: Jun Du, Jun Shi, Dongdong Sun, Yifei Wang, Guanfeng Liu, Jingru Chen, Wei Wang, Wenchao Zhou, Yushan Zheng and Haibo Wu
    Citation: Breast Cancer Research 2025 27:57
    Content type: Research Published on:

  31. Among premenopausal women, higher body mass index (BMI) is associated with lower breast cancer risk, although the underlying mechanisms are unclear. Investigating adiposity distribution may help clarify impact...

    Authors: Minouk J. Schoemaker, Taylor Ellington, Hazel B. Nichols, Lauren B. Wright, Michael E. Jones, Katie M. O’Brien, Clarice R. Weinberg, Hans-Olov Adami, Laura Baglietto, Kimberly A. Bertrand, Yu Chen, Jessica Clague DeHart, A. Heather Eliassen, Graham G. Giles, Serena C. Houghton, Victoria A. Kirsh…
    Citation: Breast Cancer Research 2025 27:55
    Content type: Research Published on:

  32. There are three categories of drugs that treat human epidermal growth factor receptor type 2 (HER-2) positive breast cancer: monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and tyrosine kinase i...

    Authors: Jinming Han, Xiaohan Zhai, Xufeng Tao, Yunming Li, Ziqi Zhao, Zhan Yu, Deshi Dong, Shilei Yang and Linlin Lv
    Citation: Breast Cancer Research 2025 27:54
    Content type: Research Published on:

  33. The insulin-like growth factor (IGF) pathway is implicated in a naturally occurring process of tissue remodeling during which cells acquire stem cell-like characteristics. We examined associations of circulati...

    Authors: Lusine Yaghjyan, Yujing J. Heng, Brian R. Sardella, Divya Murthy, Matt B. Mahoney, Bernard Rosner, Kornelia Polyak, Maisey Ratcliff and Rulla M. Tamimi
    Citation: Breast Cancer Research 2025 27:53
    Content type: Research Published on:

  34. Early prediction of treatment response to neoadjuvant therapy (NAT) in breast cancer patients can facilitate timely adjustment of treatment regimens. We aimed to develop and validate a MRI-based enhanced self-...

    Authors: Siyao Du, Wanfang Xie, Si Gao, Ruimeng Zhao, Huidong Wang, Jie Tian, Jiangang Liu, Zhenyu Liu and Lina Zhang
    Citation: Breast Cancer Research 2025 27:52
    Content type: Research Published on:

  35. Neoadjuvant checkpoint blockade immunotherapy (NATI) significantly prolonged outcomes for triple-negative breast cancer (TNBC). Residual tumor cells that survive NATI represent high-risk cell populations with ...

    Authors: Youlong Wang, Yongluo Jiang, Fadian Ding, Jun Lu, Tong Huang, Guanqing Zhong, Pengfei Zhu, Yue Ma, Jin Li, Xinjia Wang, Jiacai Lin, Hongjun Zheng, Weidong Wang, Yiwei Xu, Xiajie Lyu, Yu Si Niu…
    Citation: Breast Cancer Research 2025 27:51
    Content type: Research Published on:

  36. The role of T cell immunity during antineoplastic therapy is poorly understood. In the BEGYN-1 study, patients with breast cancer underwent quarterly assessments prior to and during antineoplastic therapy over...

    Authors: Elisabeth Kaiser, Regine Weber, Melanie Hirschstein, Hala Mazid, Emilie Marie Suzanne Kapps, Muriel Charlotte Hans, Michelle Bous, Sybelle Goedicke-Fritz, Gudrun Wagenpfeil, Michael Zemlin, Erich-Franz Solomayer, Carolin Müller and Cosima Zemlin
    Citation: Breast Cancer Research 2025 27:50
    Content type: Research Published on:

  37. Breast cancer is the most prevalent cancer in women worldwide. Aberrant epigenetic reprogramming such as dysregulation of histone acetylation has been associated with the development of breast cancer. Histone ...

    Authors: Xueying Yuan and Jeffrey M. Rosen
    Citation: Breast Cancer Research 2025 27:49
    Content type: Review Published on:

  38. Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that is an effective therapy for HER2-positive breast cancer; however, its efficacy is limited by drug resistance. While multiple mechanisms of resis...

    Authors: Barbara A. Lipert, Kyla N. Siemens, Aziza Khan, Rebecca Airey, Gech Heng Dam, Man Lu, Marcella Flinterman, Queenie Yong, Tet Woo Lee, Francis W. Hunter and Stephen M. F. Jamieson
    Citation: Breast Cancer Research 2025 27:48
    Content type: Research Published on:

  39. Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized with poor prognosis and high metastatic potential. Although traditional chemotherapy, radiation, and surgical resection...

    Authors: Fan Wang, Weina Li, Guohui Han, Jun Xie and Xiangdong Bai
    Citation: Breast Cancer Research 2025 27:47
    Content type: Research Published on:

  40. In HR+/HER2- early breast cancer (EBC) patients, approximately one-third of stage II and 50% of stage III patients experience recurrence, with poor outcomes after recurrence. Given that these patients commonly...

    Authors: Xiaoyan Wu, Yiman Li, Jilong Chen, Jie Chen, Wenchuan Zhang, Xunxi Lu, Xiaorong Zhong, Min Zhu, Yuhao Yi and Hong Bu
    Citation: Breast Cancer Research 2025 27:27
    Content type: Research Published on:

  41. Blood DNA methylation (DNAm) profiles have been used to show that changes in circulating leukocyte composition occur during breast cancer development, suggesting that peripheral immune system alterations are m...

    Authors: Jacob K. Kresovich, Brett M. Reid, Katie M. O’Brien, Zongli Xu, Doratha A. Byrd, Clarice R. Weinberg, Dale P. Sandler and Jack A. Taylor
    Citation: Breast Cancer Research 2025 27:46
    Content type: Research Published on:

  42. Accurately assessing HER2-low (immunohistochemistry [IHC] 1 + and IHC 2+/in situ hybridization [ISH]–) and HER2-ultralow (IHC > 0 < 1+) is essential given the emergence of novel therapies. Thorough understandi...

    Authors: Hong Lv, Junqiu Yue, Qingfu Zhang, Fangping Xu, Peng Gao, Haifeng Yang, Xiu Nie, Lingfei Kong, Guanjun Zhang, Jianming Li, Shiwei Xiao, Hongmei Wu, Aiyan Xing, Min Hong, Jun Fan, Huijuan Guan…
    Citation: Breast Cancer Research 2025 27:45
    Content type: Research Published on:

  43. During breast tumor progression, the transition from ductal carcinoma in situ (DCIS) to invasive breast cancer is a critical step with large implications for prognosis. However, the mechanisms of invasion are ...

    Authors: Helga Bergholtz, Jens Henrik Norum, Tonje Gulbrandsen Lien, Martina Landschoof Skrede, Øystein Garred and Therese Sørlie
    Citation: Breast Cancer Research 2025 27:44
    Content type: Research Published on:

  44. Progression from pre-cancers like ductal carcinoma in situ (DCIS) to invasive disease (cancer) is driven by somatic evolution and is altered by clinical interventions. We hypothesized that genetic and/or pheno...

    Authors: Angelo Fortunato, Diego Mallo, Luis Cisneros, Lorraine M. King, Aziz Khan, Christina Curtis, Marc D. Ryser, Joseph Y. Lo, Allison Hall, Jeffrey R. Marks, E. Shelley Hwang and Carlo C. Maley
    Citation: Breast Cancer Research 2025 27:43
    Content type: Research Published on:

  45. Recent trials have integrated immune checkpoint inhibitors (ICIs) into neoadjuvant chemotherapy (NAC) in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative ...

    Authors: Seung Ho Baek, Min Ji Lee, Yoonwon Kook, Soong June Bae, Joon Jeong, Yoon Jin Cha and Sung Gwe Ahn
    Citation: Breast Cancer Research 2025 27:42
    Content type: Research Published on:

  46. The aim of the present study was to investigate whether the androgen receptor (AR) status affects the efficacy of neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients, and to elucid...

    Authors: Ming Li, Shuling Zhou, Hong Lv, Mengyuan Cai, Ruohong Shui and Wentao Yang
    Citation: Breast Cancer Research 2025 27:41
    Content type: Research Published on:

  47. Our goal was to evaluate the impact of level of androgen receptor (AR) expression on outcomes in women with estrogen receptor α (ER) positive breast cancer. We sought to corroborate our preclinical findings th...

    Authors: James N. Ingle, Vera J. Suman, Malvika H. Solanki, Marie R. Passow, Jordan D. Campbell, Liewei Wang and Matthew P. Goetz
    Citation: Breast Cancer Research 2025 27:40
    Content type: Research Published on:

  48. Currently, the primary methods for detecting HER2 expression levels are immunohistochemistry (IHC) and in situ hybridization (ISH), with the traditional standard being a HER2-positive score of 3 + accompanied ...

    Authors: Francisco Cezar Aquino de Moraes, Caio Henrique Duarte de Castro Ribeiro, Felipe Dircêu Dantas Leite Pessôa, Juliana Ramos Chaves, Ana Paula Borges de Souza, Diego Di Felipe Ávila Alcantara, Margareth Maria Braun Guimarães Imbiriba, Maria Cristina Figueroa Magalhães and Rommel Mario Rodríguez Burbano
    Citation: Breast Cancer Research 2025 27:39
    Content type: Research Published on:

  49. Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and carries a worse prognosis relative to other breast cancer subtypes. This systematic review and meta-analysis evaluated the progno...

    Authors: Diana Zhang, Shayesteh Jahanfar, Judy B. Rabinowitz, Joshua Dower, Fei Song, Cherng-Horng Wu, Xiao Hu, Phillip Tracy, Mark Basik, Arielle Medford, Po-Han Lin, Chiun-Sheng Huang, Francois-Clement Bidard, Shufang Renault, Lori Pai, Mary Buss…
    Citation: Breast Cancer Research 2025 27:38
    Content type: Research Published on:

  50. The ataxia-telangiectasia mutated (ATM) kinase phosphorylates and activates several downstream targets that are essential for DNA damage repair, cell cycle inhibition and apoptosis. Germline biallelic inactiva...

    Authors: Nicolas M. Viart, Anne-Laure Renault, Séverine Eon-Marchais, Yue Jiao, Laetitia Fuhrmann, Sophia Murat El Houdigui, Dorothée Le Gal, Eve Cavaciuti, Marie-Gabrielle Dondon, Juana Beauvallet, Virginie Raynal, Dominique Stoppa-Lyonnet, Anne Vincent-Salomon, Nadine Andrieu, Melissa C. Southey and Fabienne Lesueur
    Citation: Breast Cancer Research 2025 27:36
    Content type: Research Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 6.1
    5-year Journal Impact Factor: 7.1
    Source Normalized Impact per Paper (SNIP): 1.865
    SCImago Journal Rank (SJR): 2.578

    Speed 2024
    Submission to first editorial decision (median days): 12
    Submission to acceptance (median days): 145

    Usage 2024
    Downloads: 2,971,481
    Altmetric mentions: 1,091

Breast Cancer Research

ISSN: 1465-542X

Contact us